Europe Pharmaceuticals Market Size and Forecast (2021 - 2031)
The European pharmaceuticals market is projected to grow significantly, reaching an estimated value of approximately US$ 446.9 billion by 2031, up from US$ 317.3 billion in 2024. This growth trajectory indicates a compound annual growth rate (CAGR) of 5.0% from 2025 to 2031, reflecting the market's robust potential.
Executive Summary and Market Overview
The European pharmaceuticals market is divided into several key regions, including Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. The growth of this market can be attributed to several factors, including a well-established healthcare infrastructure and increasing investments in research and development. Europe is home to many leading pharmaceutical and biotechnology companies that are dedicated to developing innovative treatments for various diseases, particularly chronic conditions such as cancer.
The prevalence of chronic diseases is a significant driver of pharmaceutical demand in Europe. According to the World Health Organization (WHO), as of July 2024, diabetes has emerged as one of the most prevalent chronic conditions in the region, affecting approximately 64 million adults and nearly 300,000 children and adolescents. Alarmingly, WHO estimates that one in three individuals with diabetes remains undiagnosed, and many do not achieve their treatment goals. With an aging population and rising obesity rates, projections suggest that by 2045, one in ten Europeans could be living with diabetes. Furthermore, Europe bears the highest global burden of type 1 diabetes. In 2022, the WHO reported over 4.4 million new cancer cases and nearly 2 million cancer-related deaths in Europe, underscoring the urgent need for effective pharmaceutical interventions.
The market is poised for continued expansion, particularly with advancements in immunotherapy and the development of new vaccine technologies. The European pharmaceuticals market stands as one of the largest and most dynamic globally, driven by factors such as an aging population, a rising demand for innovative treatments, and progressive regulatory frameworks.
Strategic Insights
Market Segmentation Analysis
The European pharmaceuticals market can be segmented based on various criteria:
The European pharmaceuticals market presents vast opportunities across various dimensions, driven by strong manufacturing capabilities, potential for market expansion, technological advancements, and economic contributions. The industry is undergoing a technological revolution, with significant progress in gene therapy, preventive medicine, and digital health technologies. These innovations are paving the way for biotech firms and AI-driven drug discovery, which are expected to transform patient care and treatment methodologies.
The economic impact of the pharmaceutical sector is substantial, supporting millions of jobs globally. The industry not only creates direct employment but also stimulates indirect job creation in related sectors. This highlights the potential for investment in workforce development and supply chain optimization, which can further enhance economic growth.
Moreover, artificial intelligence (AI) is revolutionizing pharmaceutical manufacturing and research and development, leading to increased efficiency and cost savings. AI solutions can significantly reduce labor costs and enhance operational efficiencies, thereby optimizing logistics and production processes. The integration of AI in drug discovery is also shortening development timelines, allowing for faster and more effective drug development.
Country Insights
The European pharmaceuticals market is further segmented by country, with the Rest of Europe holding the largest market share in 2024. Countries such as Norway, Denmark, Sweden, Poland, Switzerland, Ukraine, Romania, Belgium, and the Czech Republic are key contributors to market growth, characterized by strong healthcare systems and substantial investments in biotechnology. The Netherlands and Belgium are also central to the EU's healthcare landscape, witnessing rapid advancements in pharmaceutical research.
The increasing prevalence of chronic diseases in these regions is expected to drive pharmaceutical demand. For instance, Eurostat data indicates that cancer accounted for over 26% of total deaths in several EU countries, highlighting the urgent need for effective pharmaceutical solutions. Companies like AstriVax Therapeutics in Belgium are at the forefront of developing innovative therapies, such as DNA-based immunotherapies for chronic diseases.
Company Profiles
Key players in thean pharmaceuticals market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, and many others. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and deliver innovative solutions to consumers.
Executive Summary and Market Overview
The European pharmaceuticals market is divided into several key regions, including Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. The growth of this market can be attributed to several factors, including a well-established healthcare infrastructure and increasing investments in research and development. Europe is home to many leading pharmaceutical and biotechnology companies that are dedicated to developing innovative treatments for various diseases, particularly chronic conditions such as cancer.
The prevalence of chronic diseases is a significant driver of pharmaceutical demand in Europe. According to the World Health Organization (WHO), as of July 2024, diabetes has emerged as one of the most prevalent chronic conditions in the region, affecting approximately 64 million adults and nearly 300,000 children and adolescents. Alarmingly, WHO estimates that one in three individuals with diabetes remains undiagnosed, and many do not achieve their treatment goals. With an aging population and rising obesity rates, projections suggest that by 2045, one in ten Europeans could be living with diabetes. Furthermore, Europe bears the highest global burden of type 1 diabetes. In 2022, the WHO reported over 4.4 million new cancer cases and nearly 2 million cancer-related deaths in Europe, underscoring the urgent need for effective pharmaceutical interventions.
The market is poised for continued expansion, particularly with advancements in immunotherapy and the development of new vaccine technologies. The European pharmaceuticals market stands as one of the largest and most dynamic globally, driven by factors such as an aging population, a rising demand for innovative treatments, and progressive regulatory frameworks.
Strategic Insights
Market Segmentation Analysis
The European pharmaceuticals market can be segmented based on various criteria:
- By Molecule Type: The market is divided into Small Molecule and Biological/Biosimilar Products, with Small Molecule products holding the largest market share in 2024.
- By Indication: This includes segments for Metabolic Diseases, Cancer, Immunology, Respiratory Disorders, Cardiovascular Disorders, Neurology Disorders, Rare Diseases, and others, with Cancer being the leading segment in 2024.
- By Product Type: The market is categorized into Branded and Generic products, where Branded products dominate.
- By Drug Type: The market is further divided into Prescription and Over-the-Counter (OTC) drugs, with Prescription drugs holding the largest share.
- By Distribution Channel: This includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, with Hospital Pharmacies leading in market share.
The European pharmaceuticals market presents vast opportunities across various dimensions, driven by strong manufacturing capabilities, potential for market expansion, technological advancements, and economic contributions. The industry is undergoing a technological revolution, with significant progress in gene therapy, preventive medicine, and digital health technologies. These innovations are paving the way for biotech firms and AI-driven drug discovery, which are expected to transform patient care and treatment methodologies.
The economic impact of the pharmaceutical sector is substantial, supporting millions of jobs globally. The industry not only creates direct employment but also stimulates indirect job creation in related sectors. This highlights the potential for investment in workforce development and supply chain optimization, which can further enhance economic growth.
Moreover, artificial intelligence (AI) is revolutionizing pharmaceutical manufacturing and research and development, leading to increased efficiency and cost savings. AI solutions can significantly reduce labor costs and enhance operational efficiencies, thereby optimizing logistics and production processes. The integration of AI in drug discovery is also shortening development timelines, allowing for faster and more effective drug development.
Country Insights
The European pharmaceuticals market is further segmented by country, with the Rest of Europe holding the largest market share in 2024. Countries such as Norway, Denmark, Sweden, Poland, Switzerland, Ukraine, Romania, Belgium, and the Czech Republic are key contributors to market growth, characterized by strong healthcare systems and substantial investments in biotechnology. The Netherlands and Belgium are also central to the EU's healthcare landscape, witnessing rapid advancements in pharmaceutical research.
The increasing prevalence of chronic diseases in these regions is expected to drive pharmaceutical demand. For instance, Eurostat data indicates that cancer accounted for over 26% of total deaths in several EU countries, highlighting the urgent need for effective pharmaceutical solutions. Companies like AstriVax Therapeutics in Belgium are at the forefront of developing innovative therapies, such as DNA-based immunotherapies for chronic diseases.
Company Profiles
Key players in thean pharmaceuticals market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, and many others. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and deliver innovative solutions to consumers.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
3.3 Assumptions and Limitations
4. PHARMACEUTICAL MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Regulatory Landscape
4.2.1 Europe
4.3 List of Key Suppliers:
4.4 Average selling Price:
4.5 Sourcing Strategy:
4.6 Market Entry Barriers in the Global Pharmaceutical Market:
4.7 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
5. EUROPE PHARMACEUTICAL MARKET – KEY MARKET DYNAMICS
5.1 Europe Pharmaceutical Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Global Disease Burden and Increasing Demand for Innovative Treatments
5.2.2 Expanding Global Access to Medicines and Growing Emerging Markets
5.3 Market Restraints
5.3.1 Regulatory Pressures and Market Shifts
5.4 Market Opportunities
5.4.1 Harnessing Innovation, AI, and Market Expansion
5.5 Future Trends
5.5.1 Regional Power Shifts, Supply Chain Diversification, and Regulatory Evolution
5.6 Impact of Drivers and Restraints:
6. PHARMACEUTICAL MARKET – EUROPE ANALYSIS
6.1 Europe Pharmaceutical Market Revenue (US$ Billion), 2021–2031
6.2 Europe Pharmaceutical Market Forecast Analysis
7. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY MOLECULE TYPE
7.1 Small Molecule
7.1.1 Overview
7.1.2 Small Molecule: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.2 Biological and Biosimilar Products
7.2.1 Overview
7.2.2 Biological and Biosimilar Products: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY INDICATION
8.1 Metabolic Diseases
8.1.1 Overview
8.1.2 Metabolic Diseases: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.2 Cancer
8.2.1 Overview
8.2.2 Cancer: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.3 Immunology
8.3.1 Overview
8.3.2 Immunology: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.4 Respiratory Disorder
8.4.1 Overview
8.4.2 Respiratory Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.5 Cardiovascular Disorder
8.5.1 Overview
8.5.2 Cardiovascular Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.6 Neurology Disorder
8.6.1 Overview
8.6.2 Neurology Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.7 Rare Disease
8.7.1 Overview
8.7.2 Rare Disease: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY PRODUCT
9.1 Branded
9.1.1 Overview
9.1.2 Branded: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9.2 Generic
9.2.1 Overview
9.2.2 Generic: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY TYPE
10.1 Prescription
10.1.1 Overview
10.1.2 Prescription: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.2 OTC Drugs
10.2.1 Overview
10.2.2 OTC Drugs: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY DISTRIBUTION CHANNEL
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12. EUROPE PHARMACEUTICAL MARKET – COUNTRY ANALYSIS
12.1 Europe
12.1.1 Europe Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.1 Europe Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.2 United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.2.1 United Kingdom: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.2.2 United Kingdom: Europe Pharmaceutical Market Share – by Indication
12.1.1.2.3 United Kingdom: Europe Pharmaceutical Market Share – by Product
12.1.1.2.4 United Kingdom: Europe Pharmaceutical Market Share – by Type
12.1.1.2.5 United Kingdom: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.3 Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.3.1 Germany: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.3.2 Germany: Europe Pharmaceutical Market Share – by Indication
12.1.1.3.3 Germany: Europe Pharmaceutical Market Share – by Product
12.1.1.3.4 Germany: Europe Pharmaceutical Market Share – by Type
12.1.1.3.5 Germany: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.4 France: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.4.1 France: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.4.2 France: Europe Pharmaceutical Market Share – by Indication
12.1.1.4.3 France: Europe Pharmaceutical Market Share – by Product
12.1.1.4.4 France: Europe Pharmaceutical Market Share – by Type
12.1.1.4.5 France: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.5 Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.5.1 Italy: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.5.2 Italy: Europe Pharmaceutical Market Share – by Indication
12.1.1.5.3 Italy: Europe Pharmaceutical Market Share – by Product
12.1.1.5.4 Italy: Europe Pharmaceutical Market Share – by Type
12.1.1.5.5 Italy: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.6 Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.6.1 Spain: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.6.2 Spain: Europe Pharmaceutical Market Share – by Indication
12.1.1.6.3 Spain: Europe Pharmaceutical Market Share – by Product
12.1.1.6.4 Spain: Europe Pharmaceutical Market Share – by Type
12.1.1.6.5 Spain: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.7 Switzerland: Pharmaceutical Market – Revenue, 2021 - 2031 (US$ Billion)
12.1.1.7.1 Switzerland: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.7.2 Switzerland: Europe Pharmaceutical Market Share – by Indication
12.1.1.7.3 Switzerland: Europe Pharmaceutical Market Share – by Product
12.1.1.7.4 Switzerland: Europe Pharmaceutical Market Share – by Type
12.1.1.7.5 Switzerland: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.8 Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.8.1 Rest of Europe: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.8.2 Rest of Europe: Europe Pharmaceutical Market Share – by Indication
12.1.1.8.3 Rest of Europe: Europe Pharmaceutical Market Share – by Product
12.1.1.8.4 Rest of Europe: Europe Pharmaceutical Market Share – by Type
12.1.1.8.5 Rest of Europe: Europe Pharmaceutical Market Share – by Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1 Company Market Share Analysis
14. INDUSTRY LANDSCAPE
14.1 Overview
14.2 Expansion
14.3 New Product Development
14.4 Merger and Acquisition
14.5 Partnerships
14.6 Other Business Strategies
15. COMPANY PROFILES
15.1 Johnson & Johnson
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Merck & Co Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Eli Lilly and Co
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Financial Overview
15.4.4 SWOT Analysis
15.4.5 Key Developments
15.5 Bristol-Myers Squibb Co
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 ESTEVE
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 UCB SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Teva Pharmaceutical Industries Ltd
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Hikma Pharmaceuticals Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Viatris Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 AstraZeneca Plc
15.11.1 1Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 Sanofi SA
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
15.13 GSK Plc
15.13.1 Key Facts
15.13.2 Business Description
15.13.3 Products and Services
15.13.4 Financial Overview
15.13.5 SWOT Analysis
15.13.6 Key Developments
15.14 F. Hoffmann-La Roche Ltd
15.14.1 Key Facts
15.14.2 Business Description
15.14.3 Products and Services
15.14.4 Financial Overview
15.14.5 SWOT Analysis
15.14.6 Key Developments
15.15 Novartis AG
15.15.1 Key Facts
15.15.2 Business Description
15.15.3 Products and Services
15.15.4 Financial Overview
15.15.5 SWOT Analysis
15.15.6 Key Developments
15.16 AbbVie Inc
15.16.1 Key Facts
15.16.2 Business Description
15.16.3 Products and Services
15.16.4 Financial Overview
15.16.5 SWOT Analysis
15.16.6 Key Developments
16. APPENDIX
16.1 Glossary of Terms
16.2 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
3.3 Assumptions and Limitations
4. PHARMACEUTICAL MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Regulatory Landscape
4.2.1 Europe
4.3 List of Key Suppliers:
4.4 Average selling Price:
4.5 Sourcing Strategy:
4.6 Market Entry Barriers in the Global Pharmaceutical Market:
4.7 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
5. EUROPE PHARMACEUTICAL MARKET – KEY MARKET DYNAMICS
5.1 Europe Pharmaceutical Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Global Disease Burden and Increasing Demand for Innovative Treatments
5.2.2 Expanding Global Access to Medicines and Growing Emerging Markets
5.3 Market Restraints
5.3.1 Regulatory Pressures and Market Shifts
5.4 Market Opportunities
5.4.1 Harnessing Innovation, AI, and Market Expansion
5.5 Future Trends
5.5.1 Regional Power Shifts, Supply Chain Diversification, and Regulatory Evolution
5.6 Impact of Drivers and Restraints:
6. PHARMACEUTICAL MARKET – EUROPE ANALYSIS
6.1 Europe Pharmaceutical Market Revenue (US$ Billion), 2021–2031
6.2 Europe Pharmaceutical Market Forecast Analysis
7. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY MOLECULE TYPE
7.1 Small Molecule
7.1.1 Overview
7.1.2 Small Molecule: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.2 Biological and Biosimilar Products
7.2.1 Overview
7.2.2 Biological and Biosimilar Products: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY INDICATION
8.1 Metabolic Diseases
8.1.1 Overview
8.1.2 Metabolic Diseases: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.2 Cancer
8.2.1 Overview
8.2.2 Cancer: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.3 Immunology
8.3.1 Overview
8.3.2 Immunology: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.4 Respiratory Disorder
8.4.1 Overview
8.4.2 Respiratory Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.5 Cardiovascular Disorder
8.5.1 Overview
8.5.2 Cardiovascular Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.6 Neurology Disorder
8.6.1 Overview
8.6.2 Neurology Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.7 Rare Disease
8.7.1 Overview
8.7.2 Rare Disease: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY PRODUCT
9.1 Branded
9.1.1 Overview
9.1.2 Branded: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9.2 Generic
9.2.1 Overview
9.2.2 Generic: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY TYPE
10.1 Prescription
10.1.1 Overview
10.1.2 Prescription: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.2 OTC Drugs
10.2.1 Overview
10.2.2 OTC Drugs: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY DISTRIBUTION CHANNEL
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12. EUROPE PHARMACEUTICAL MARKET – COUNTRY ANALYSIS
12.1 Europe
12.1.1 Europe Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.1 Europe Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.2 United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.2.1 United Kingdom: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.2.2 United Kingdom: Europe Pharmaceutical Market Share – by Indication
12.1.1.2.3 United Kingdom: Europe Pharmaceutical Market Share – by Product
12.1.1.2.4 United Kingdom: Europe Pharmaceutical Market Share – by Type
12.1.1.2.5 United Kingdom: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.3 Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.3.1 Germany: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.3.2 Germany: Europe Pharmaceutical Market Share – by Indication
12.1.1.3.3 Germany: Europe Pharmaceutical Market Share – by Product
12.1.1.3.4 Germany: Europe Pharmaceutical Market Share – by Type
12.1.1.3.5 Germany: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.4 France: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.4.1 France: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.4.2 France: Europe Pharmaceutical Market Share – by Indication
12.1.1.4.3 France: Europe Pharmaceutical Market Share – by Product
12.1.1.4.4 France: Europe Pharmaceutical Market Share – by Type
12.1.1.4.5 France: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.5 Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.5.1 Italy: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.5.2 Italy: Europe Pharmaceutical Market Share – by Indication
12.1.1.5.3 Italy: Europe Pharmaceutical Market Share – by Product
12.1.1.5.4 Italy: Europe Pharmaceutical Market Share – by Type
12.1.1.5.5 Italy: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.6 Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.6.1 Spain: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.6.2 Spain: Europe Pharmaceutical Market Share – by Indication
12.1.1.6.3 Spain: Europe Pharmaceutical Market Share – by Product
12.1.1.6.4 Spain: Europe Pharmaceutical Market Share – by Type
12.1.1.6.5 Spain: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.7 Switzerland: Pharmaceutical Market – Revenue, 2021 - 2031 (US$ Billion)
12.1.1.7.1 Switzerland: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.7.2 Switzerland: Europe Pharmaceutical Market Share – by Indication
12.1.1.7.3 Switzerland: Europe Pharmaceutical Market Share – by Product
12.1.1.7.4 Switzerland: Europe Pharmaceutical Market Share – by Type
12.1.1.7.5 Switzerland: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.8 Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.8.1 Rest of Europe: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.8.2 Rest of Europe: Europe Pharmaceutical Market Share – by Indication
12.1.1.8.3 Rest of Europe: Europe Pharmaceutical Market Share – by Product
12.1.1.8.4 Rest of Europe: Europe Pharmaceutical Market Share – by Type
12.1.1.8.5 Rest of Europe: Europe Pharmaceutical Market Share – by Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1 Company Market Share Analysis
14. INDUSTRY LANDSCAPE
14.1 Overview
14.2 Expansion
14.3 New Product Development
14.4 Merger and Acquisition
14.5 Partnerships
14.6 Other Business Strategies
15. COMPANY PROFILES
15.1 Johnson & Johnson
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Merck & Co Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Eli Lilly and Co
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Financial Overview
15.4.4 SWOT Analysis
15.4.5 Key Developments
15.5 Bristol-Myers Squibb Co
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 ESTEVE
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 UCB SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Teva Pharmaceutical Industries Ltd
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Hikma Pharmaceuticals Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Viatris Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 AstraZeneca Plc
15.11.1 1Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 Sanofi SA
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
15.13 GSK Plc
15.13.1 Key Facts
15.13.2 Business Description
15.13.3 Products and Services
15.13.4 Financial Overview
15.13.5 SWOT Analysis
15.13.6 Key Developments
15.14 F. Hoffmann-La Roche Ltd
15.14.1 Key Facts
15.14.2 Business Description
15.14.3 Products and Services
15.14.4 Financial Overview
15.14.5 SWOT Analysis
15.14.6 Key Developments
15.15 Novartis AG
15.15.1 Key Facts
15.15.2 Business Description
15.15.3 Products and Services
15.15.4 Financial Overview
15.15.5 SWOT Analysis
15.15.6 Key Developments
15.16 AbbVie Inc
15.16.1 Key Facts
15.16.2 Business Description
15.16.3 Products and Services
15.16.4 Financial Overview
15.16.5 SWOT Analysis
15.16.6 Key Developments
16. APPENDIX
16.1 Glossary of Terms
16.2 About The Insight Partners
LIST OF TABLES
Table 1. Europe Pharmaceutical Market Segmentation
Table 2. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Table 3. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Molecule Type
Table 4. Table: Top-Selling Drugs in 2021
Table 5. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Indication
Table 6. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Product
Table 7. Key brands facing patent expirations
Table 8. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Type
Table 9. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Distribution Channel
Table 10. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Country
Table 11. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 12. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 13. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 14. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 15. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 16. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 17. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 18. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 19. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 20. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 21. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 22. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 23. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 24. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 25. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 26. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 27. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 28. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 29. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 30. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 31. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 32. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 33. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 34. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 35. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 36. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 37. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 38. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 39. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 40. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 41. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 42. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 43. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 44. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 45. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 46. Company Market Share Analysis
Table 47. Glossary of Terms, Pharmaceutical Market
Table 1. Europe Pharmaceutical Market Segmentation
Table 2. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Table 3. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Molecule Type
Table 4. Table: Top-Selling Drugs in 2021
Table 5. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Indication
Table 6. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Product
Table 7. Key brands facing patent expirations
Table 8. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Type
Table 9. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Distribution Channel
Table 10. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Country
Table 11. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 12. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 13. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 14. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 15. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 16. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 17. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 18. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 19. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 20. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 21. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 22. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 23. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 24. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 25. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 26. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 27. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 28. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 29. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 30. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 31. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 32. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 33. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 34. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 35. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 36. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 37. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 38. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 39. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 40. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 41. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 42. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 43. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 44. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 45. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 46. Company Market Share Analysis
Table 47. Glossary of Terms, Pharmaceutical Market
LIST OF FIGURES
Figure 1. Europe Pharmaceutical Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Pharmaceutical Market Revenue (US$ Billion), 2021–2031
Figure 5. Europe Pharmaceutical Market Share (%) – by Molecule Type (2024 and 2031)
Figure 6. Small Molecule: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 7. Biological and Biosimilar Products: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 8. Europe Pharmaceutical Market Share (%) – by Indication (2024 and 2031)
Figure 9. Metabolic Diseases: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 10. Cancer: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 11. Immunology: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 12. Respiratory Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 13. Cardiovascular Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 14. Neurology Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 15. Rare Disease: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 16. Others: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 17. Europe Pharmaceutical Market Share (%) – by Product (2024 and 2031)
Figure 18. Branded: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 19. Generic: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 20. Europe Pharmaceutical Market Share (%) – by Type (2024 and 2031)
Figure 21. Prescription: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 22. OTC Drugs: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 23. Europe Pharmaceutical Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 24. Hospital Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 25. Retail Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 26. Online Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 27. Europe Pharmaceutical Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 28. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 29. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 30. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 31. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 32. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 33. Switzerland: Pharmaceutical Market – Revenue, 2021 - 2031 (US$ Billion)
Figure 34. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 1. Europe Pharmaceutical Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Pharmaceutical Market Revenue (US$ Billion), 2021–2031
Figure 5. Europe Pharmaceutical Market Share (%) – by Molecule Type (2024 and 2031)
Figure 6. Small Molecule: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 7. Biological and Biosimilar Products: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 8. Europe Pharmaceutical Market Share (%) – by Indication (2024 and 2031)
Figure 9. Metabolic Diseases: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 10. Cancer: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 11. Immunology: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 12. Respiratory Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 13. Cardiovascular Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 14. Neurology Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 15. Rare Disease: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 16. Others: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 17. Europe Pharmaceutical Market Share (%) – by Product (2024 and 2031)
Figure 18. Branded: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 19. Generic: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 20. Europe Pharmaceutical Market Share (%) – by Type (2024 and 2031)
Figure 21. Prescription: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 22. OTC Drugs: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 23. Europe Pharmaceutical Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 24. Hospital Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 25. Retail Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 26. Online Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 27. Europe Pharmaceutical Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 28. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 29. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 30. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 31. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 32. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 33. Switzerland: Pharmaceutical Market – Revenue, 2021 - 2031 (US$ Billion)
Figure 34. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
